Business
REGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights
- RGX-314 subretinal pivotal wet AMD trial expected to initiate in Q1 2021 - Enrollment continues in RGX-314 suprachoroidal Phase II AAVIATE study; initial
About this update from Regenxbio Inc.
[{"type":"text","content":"- RGX-314 subretinal pivotal wet AMD trial expected to initiate in Q1 2021\n - Enrollment continues in RGX-314 suprachoroidal Phase II AAVIATE study; initial safety data expected in early 2021\n - RGX-314 suprachoroidal Phase II ALTITUDE trial is active and expects to initiate enrollment by end of 2020; initial data expected in 2021\n - Additional patients enrolled in expanded Phase I/II study of RGX-121 for the treatment of MPS II; further updates from ongoing trial anticipated by end of 2020\n - $80 million milestone payment from Novartis received in October 2020\n - $290 million in cash, cash equivalents and marketable securities as of September 30, 2020\n - Q3 earnings conference call Wednesday, November 4 at 4:30 p.m. ET\n\n\nROCKVILLE, Md., Nov. 4, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended September 30, 2020, and recent operational highlights.\n\"We have made several important advancements in our clinical pipeline during the third quarter of 2020, with continued focus on execution during the COVID-19 pandemic. I'm pleased that two Phase II trials are underway for the treatment of wet AMD and diabetic retinopathy using the suprachoroidal approach for the delivery of RGX-314. In addition, we have expanded our RGX-121 program for patients with MPS II to gain additional insight into the potential treatment effects of this one-time gene therapy candidate in more patients, and we have dosed additional patients in the second cohort of the ongoing Phase I/II trial. I look forward to providing additional updates on all of our clinical programs in 2021, as we continue to focus on the significant unmet medical needs in both large indications and rare diseases,\" said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO.\n\"The overall progress of gene therapy treatments continues to be encouraging, as we see additional patients around the world treated with Zolgensma®, the first approved gene therapy based on REGENXBIO's NAV Technology Platform,\" continued Mr. Mills. \"We maintain our focus on our important relationships with partners and licensees in the gene therapy space, with a str...